证券代码：430478 证券简称：峆一药业 公告编号：2023-058 安徽峆一药业股份有限公司 第四届董事会第十二次会议决议公告 4.发出董事会会议通知的时间和方式：2023 年 10 月 7 日以通讯及书面方式 发出 5.会议主持人：董事长董来山先生 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 2.会议召开地点：公司会议室 3.会议召开方式：现场 6.会议列席人员：公司董事、监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集召开符合《公司法》和《公司章程》的有关规定，所作的决 议合法有效。 （一）会议召开情况 1.会议召开时间：2023 年 10 月 11 日 本议案不涉及关联交易事项，无需回避表决。 4.提交股东大会表决情况： 本议案无需提交股东大会审议。 （二）审议通过《关于对外投资设立合资子公司的议案》 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于对外投资设立全资子公司的议案 ...

证券代码：430478 证券简称：峆一药业 公告编号：2023-057 关于对外投资设立合资子公司的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、对外投资概述 （一）基本情况 根据公司的发展经营规划，公司拟使用自有资金与韩国达善（Dasan Pharmaceuticals, Co., Ltd.）共同合资设立子公司，从事药物制剂的生产及销售， 拟成立的合资公司注册地址暂定为：安徽省滁州高新区经十一路。合资子公司 注册资本为人民币一亿元，其中公司出资 7,000 万元，出资占比 70%；韩国达 善出资 3,000 万元，出资占比 30%。具体的子公司名称、注册资本、注册地址、 经营范围等以当地市场监督管理部门登记为准。 安徽峆一药业股份有限公司 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 根据《上市公司重大资产重组管理办法》的相关规定，公司本次对外投资 系新设子公司，不构成重大资产重组。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）审议和表决情况 公司第四届董事会于 2 ...

专利权人： 安徽峆一药业股份有限公司 证券代码：430478 证券简称： 峆一药业 公告编号： 2023-055 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 安徽峆一药业股份有限公司(以下简称"公司")于2023年9月14日收到由国 家知识产权局颁发的一项《发明专利证书》。具体情况如下： 发明名称： 一种拉多替尼的高收率合成方法 专利号： ZL 2019 1 1282510.1 2023 年 9 月 14 日 授权公告日： 2023 年 09月 12日 授权公告号： CN 111039932 B 对公司的影响 上述发明专利证书为公司自主研发取得，有利于提升公司产品的自主知识 产权优势，加强对知识产权的保护力度，增强公司的核心竞争力，对公司未来的 经营发展具有积极意义。 (一) 《发明专利证书》(证书号 第 6313831 号) 安徽峆一药业股份有限公司 董事会 ...

证券代码：430478 证券简称： 峆一药业 公告编号： 2023-054 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 发明名称： 一种尼洛替尼的高收率合成方法 专利号： ZL 2019 1 1289385.7 专利权人： 安徽峆一药业股份有限公司 授权公告日： 2023 年 09月 08日 授权公告号： CN 110872279 B 对公司的影响 上述发明专利证书为公司自主研发取得，有利于提升公司产品的自主知识 产权优势，加强对知识产权的保护力度，增强公司的核心竞争力，对公司未来的 经营发展具有积极意义。 安徽峆一药业股份有限公司(以下简称"公司")于2023年9月11日收到由国 家知识产权局颁发的一项《发明专利证书》。具体情况如下： 2023 年 9 月 11 日 (一) 《发明专利证书》(证书号 第 6306017 号) 安徽峆一药业股份有限公司 董事会 ...

证券代码：430478 证券简称：峆一药业 公告编号：2023-053 安徽峆一药业股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 公司按照本次发行价格 12.62 元/股，在初始发行规模 880.00 万股的基础 上全额行使超额配售选择权新增发行股票数量 1,012.00 万股，公司由此增加的 募集资金总额为 1665.84 万元，扣除发行费用（不含税）金额为 157.66 万元， 该部分的募集资金净额为人民币 1508.18 万元。截至 2023 年 03 月 27 日，上 述募集资金已全部到账，并由容诚会计师事务所（特殊普通合伙）进行审验，出 具了《验资报告》（容诚验字[2023]230Z0073 号）。基于此，公司总股本由 3,003.75 万股加至 4,015.75 万股，发行总股数占发行后总股本的 25.20%。公 司由此增加的募集资金总额为 1665.84 万元，连同初始发行规模 880.00 万股股 票对应的募集资金总 ...

安徽峆一药业股份有限公司 第四届董事会第十一次会议决议公告 证券代码：430478 证券简称：峆一药业 公告编号：2023-051 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一）会议召开情况 1.会议召开时间：2023 年 8 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出董事会会议通知的时间和方式：2023 年 8 月 17 日以通讯及书面方式 发出 5.会议主持人：董事长董来山先生 6.会议列席人员：公司董事、监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集召开符合《公司法》和《公司章程》的有关规定，所作的决 议合法有效。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 一、会议召开和出席情况 本议案无需提交股东大会审议。 （二）审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的专项 报告的议案》 二、议案审议情况 （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 1.议案内容： ...

证券代码：430478 证券简称：峆一药业 公告编号：2023-052 安徽峆一药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2023 年 8 月 17 日 以通讯及书面方式发出 5.会议主持人：监事会主席方文俊先生 6.召开情况合法、合规、合章程性说明： （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 1.议案内容： 详细内容见公司 2023 年 8 月 29 日于北京证券交易所信息披露平台 （www.bse.cn）披露的《安徽峆一药业股份有限公司 2023 年半年度报告》（公告 编号：2023-049）和《安徽峆一药业股份有限公司 2023 年半年度报告摘要》（公 告编号：2023-050）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥123,194,085.56, a decrease of 10.50% compared to ¥137,642,884.96 in the same period last year[25]. - The net profit attributable to shareholders of the listed company increased by 6.37% to ¥36,561,135.39, compared to ¥34,370,786.76 in the previous year[25]. - The company achieved a gross profit margin of 36.81%, down from 40.49% in the same period last year[25]. - The net profit for the period was ¥36,561,135.39, an increase of 6.37% from the previous year's ¥34,370,786.76[39]. - The company reported a total profit for the first half of 2023 of CNY 41,496,449.03, an increase of 22.8% from CNY 33,814,770.91 in the first half of 2022[124]. - The company reported a net profit margin improvement, with net income figures to be detailed in future reports, indicating potential profitability enhancement strategies[119]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥514,796,284.12, reflecting a growth of 35.52% from ¥380,716,880.35 at the end of the previous year[27]. - The company's total liabilities were ¥56,818,203.34, a slight increase of 1.72% from ¥55,857,207.55 at the end of the previous year[27]. - Total assets increased by 35.52% to ¥514,796,284.12 from ¥380,716,880.35 at the beginning of the period[39]. - Total liabilities rose by 1.72% to ¥56,818,203.34 from ¥55,857,207.55, mainly due to increased procurement during the period[39]. - The total liabilities amounted to CNY 56,818,203.34, compared to CNY 55,857,207.55 in the previous year, indicating a slight increase in leverage[112]. Cash Flow - The company's net cash flow from operating activities was ¥24,054,023.26, down 48.01% from ¥46,268,074.63 in the same period last year[28]. - The cash flow from operating activities has decreased by 48.01% to ¥24,054,023.26, primarily due to increased purchases and tax payments[67]. - The net cash flow from operating activities was 17,634,955.79, a decrease of 55.3% compared to 39,398,685.28 in the previous period[132]. - The net cash flow from investing activities was -125,778,303.62, compared to -20,474,255.64 in the previous period, indicating a significant increase in investment outflows[132]. - The total cash and cash equivalents at the end of the period were 49,661,051.67, down from 54,554,531.20 at the beginning of the period, reflecting a net decrease of 4,893,479.53[133]. Shareholder Equity and Dividends - The company completed a cash dividend distribution of ¥12,047,250.00, distributing ¥3.0 per 10 shares to all shareholders[6]. - The total equity attributable to shareholders increased by 43.57% to ¥443,675,993.15, compared to ¥309,025,777.03 in the previous year[27]. - The total equity attributable to shareholders at the end of the period was 457,978,080.78, reflecting an increase from the previous period's balance[135]. - The profit distribution included a distribution to owners (or shareholders) amounting to RMB -9,011,250.00, indicating a reduction in retained earnings[141]. Research and Development - The company holds 6 invention patents and 19 utility model patents, indicating a strong focus on R&D and innovation[34]. - Research and development expenses have risen by 11.82% to ¥7,491,375.95, indicating a focus on innovation[54]. - Research and development expenses increased to CNY 7,491,375.95 in the first half of 2023, up from CNY 6,699,468.14 in the same period of 2022, reflecting a focus on innovation[119]. Market and Operational Risks - The company faced a risk where sales to its top five customers accounted for 59.34% of total operating income, indicating a high concentration risk[79]. - The company is exposed to fluctuations in raw material prices, which can significantly impact profitability due to the cyclical nature of the industry[79]. - The company is actively monitoring and adapting to changes in international trade policies that may affect its export markets, particularly in South Korea and Japan[79]. Corporate Governance and Compliance - The company has maintained a stable board with no changes in the chairman or general manager during the reporting period[100]. - The number of independent directors remains unchanged, ensuring continuity in governance[100]. - The financial statements were approved for release by the board of directors on August 28, 2023, ensuring timely reporting[150]. - The company has not reported any significant changes in related party transactions or control relationships during the reporting period[143]. Employee and Operational Metrics - The total number of employees increased from 366 to 423, representing a growth of approximately 15.6%[103]. - The number of management personnel increased from 16 to 17, while production personnel rose from 227 to 271[103].

Financial Performance - Net profit attributable to shareholders decreased by 24.51% to CNY 13,875,693.85 year-on-year[10] - Operating revenue declined by 5.91% to CNY 66,663,253.61 compared to the same period last year[10] - The net cash flow from operating activities turned negative at CNY -6,383,753.48, a decrease of 135.73% year-on-year[10] - Total operating revenue for Q1 2023 was ¥66,663,253.61, a decrease from ¥70,853,210.95 in Q1 2022[33] - Net profit for Q1 2023 was ¥12,931,524.95, down from ¥17,905,085.94 in Q1 2022, representing a decline of approximately 28.5%[34] - Basic and diluted earnings per share for Q1 2023 were both ¥0.42, compared to ¥0.61 in Q1 2022[35] - Operating revenue for Q1 2023 was approximately ¥49.63 million, a decrease of 20.9% compared to ¥62.75 million in Q1 2022[37] - Net profit for Q1 2023 reached ¥14.76 million, representing an increase of 4.7% from ¥14.10 million in Q1 2022[37] - The total comprehensive income for Q1 2023 was ¥14.76 million, compared to ¥14.10 million in Q1 2022[38] Assets and Liabilities - Total assets increased by 31.39% to CNY 500,231,235.48 compared to the end of last year[10] - The company's total liabilities to assets ratio decreased to 10.46% from 14.67% at the end of the previous year[10] - Total current assets increased to ¥331,426,442.96 as of March 31, 2023, up from ¥211,003,184.81 at December 31, 2022, representing a growth of 57.1%[27] - Total assets reached ¥500,231,235.48, up from ¥380,716,880.35, indicating an increase of 31.5%[28] - Total liabilities decreased to ¥52,303,707.00 from ¥55,857,207.55, a reduction of 6.5%[29] - Shareholders' equity increased significantly to ¥447,927,528.48 from ¥324,859,672.80, representing a growth of 38.0%[29] - Total liabilities increased to ¥34,124,938.73 from ¥33,758,192.20[32] - Shareholders' equity rose to ¥429,125,817.74 from ¥304,232,437.50[32] Cash Flow - The company’s fundraising activities resulted in an increase in cash flow from financing activities compared to the previous year[14] - Cash flow from operating activities showed a net outflow of ¥6.38 million in Q1 2023, compared to a net inflow of ¥17.87 million in Q1 2022[41] - Cash and cash equivalents at the end of Q1 2023 totaled ¥127.01 million, significantly up from ¥21.10 million at the end of Q1 2022[41] - The net increase in cash and cash equivalents was $67.86 million, contrasting with a decrease of -$19.42 million last year[43] - Cash received from sales of goods and services was $30.45 million, compared to $64.90 million previously[43] - Cash paid for purchasing goods and services was $27.39 million, down from $39.74 million[43] - Cash received from other operating activities was $7.54 million, significantly higher than $82,081.10 last year[43] Shareholder Information - The number of ordinary shareholders increased to 2,638 by the end of the reporting period[16] - The company has fulfilled all disclosed commitments without any significant changes during the reporting period[23] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,703,920.95 during the reporting period[13] Research and Development - Research and development expenses for Q1 2023 were ¥3,555,986.54, compared to ¥2,873,311.18 in Q1 2022, indicating a growth of approximately 23.7%[33] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[30] Operational Stability - The company has no ongoing litigation or arbitration matters, ensuring a stable operational environment[22] - There were no major acquisitions or asset sales reported during the quarter, indicating a focus on internal growth[22] - The company has maintained a strong financial position with no external guarantees or loans provided[22] - The company has a robust internal audit process in place, ensuring compliance with financial reporting standards[26] Inventory and Other Assets - The company reported a notable increase in inventory, which rose to ¥68,643,278.96 from ¥67,368,365.91, an increase of 1.9%[27] - The company has maintained a strong capital reserve, which increased to ¥134,202,020.33 from ¥34,185,689.60, a growth of 292.5%[29] - Total non-current assets decreased slightly to ¥168,804,792.52 from ¥169,713,695.54, a decline of 0.5%[28] - Total assets pledged amounted to 13,368,031.17, representing 2.67% of total assets, primarily due to bank acceptance bills and guarantees[24] User Data and Market Expansion - The company reported a significant increase in user data, with a growth rate of 62.46% compared to the previous period[19] - The company is actively monitoring market expansion opportunities but has not disclosed specific new products or technologies in development[22]

证券代码：430478 证券简称： 峆一药业 公告编号：2023-038 2022 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 安徽峆一药业股份有限公司（以下简称"公司"）已于 2023 年4 月14日在北京 证券交易所指定信息披露平台（http://www.bse.cn/）披露《2022 年年度报告》 （公告编号： 2023-019），为便于广大投资者更深入全面地了解公司情况，加强与 投资者的互动交流，公司将召开2022 年年度网上业绩说明会。 （一）会议召开时间： 2023 年 4 月 2 7 日（星期四）15:00-17:00 。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行， 投资者可登录中证路演中心 （https://www.cs.com.cn/roadshow/）参与本次年报业绩说明会。 公司董事长、总经理：董来山先生 公司董事会秘书： 董来高先生 公司财务负责人： 陈康先生 联系人：董来高 本次说明会采用网络方式召开。 电话： 0550-7764800 为充分尊重投资者， ...